Treatment Overview

The AML treatment that a patient receives depends on a number of factors, for example, age, other medical conditions and the specific type of AML that the person is suffering from.

Patients who are “fit” (no prior significant medical conditions) and under 70 years old are usually given intravenous (IV) chemotherapy, which requires hospitalisation for 3–4 weeks. Older and more “frail” (patients with serious prior medical conditions) patients may be given different treatment options, such as subcutaneous (applied under the skin) or oral (taken by the mouth) therapies.

Watch the videos in this section to learn more about various treatment options available for AML and to gain a better understanding of how to best approach your doctors with treatment questions.



Ask the Expert: Understanding & Managing My AML Diagnosis

Leading AML expert Dr. Gail Roboz answered questions from the Patient Power community. Watch the replay to learn about AML genetic research, prognostic factors, treatment options and more.


What Tests Are Used to Assess AML Treatment Response?

What tests help with assessing AML treatment response? Watch as Dr. Daniel Pollyea explains tests for AML patients to identify risk factors, guide treatment and evaluate response.


What’s the Course of Care for AML Patients Who Relapse?

How long will AML remission last? What options do relapsed patients have? Watch now as Dr. Daniel Pollyea discusses treatment goals, remission duration and next steps after a relapse.


Where Does Transplant Fit Into AML Care?

During this Ask the Expert segment, Dr. Daniel Pollyea explains the role of transplant in AML care, how it has changed and good candidates for transplant. Watch now to learn more.


AML Treatment: Benefits of Avoiding High-Dose Chemotherapy

Should AML patients stay away from intensive chemotherapy? Watch as Dr. Daniel Pollyea discusses treatment toxicities, research advances and where AML chemotherapy fits in.


AML Venetoclax Treatment Regimen: Understanding Dosage

How do doctors balance treatment efficacy and toxicity for AML patients on venetoclax? Tune in to hear expert Dr. Daniel Pollyea explain the dosage considerations.


What Is the Treatment Approach for Patients With Secondary AML?

What is the course of care for people who develop secondary AML? Tune in to hear expert Dr. Uma Borate discuss disease presentation, treatment strategy and more.


Post-ASCO 2019: Identifying and Treating AML Genetic Subtypes

What does mutational status mean for AML patients? Watch as Dr. Eytan Stein breaks down patient subsets of AML and shares the latest research.


Will Novel Agents Benefit the Older AML Patient Population?

Dr. Daniel Pollyea discusses the course of care and quality of life for older AML patients. Watch now to learn about treatment tolerability, side effects novel agent outcomes.


Showing 9 of 66 programs
Join Our Community Register for Events Read Our Latest Blog

Page last updated on August 13, 2019